spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online March 31, 2007
Journal of Experimental Biology 210, 1455-1462 (2007)
Published by The Company of Biologists 2007
doi: 10.1242/jeb.02756
This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu-Snyder, P.
Right arrow Articles by Borgens, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu-Snyder, P.
Right arrow Articles by Borgens, R. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Neuroprotection from secondary injury by polyethylene glycol requires its internalization

Peishan Liu-Snyder1, Melissa Peasley Logan1, Riyi Shi1,2, Daniel T. Smith3 and Richard Ben Borgens1,2,*

1 Center for Paralysis Research, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
2 Weldon School of Biomedical Engineering, College of Engineering, Purdue University, West Lafayette, IN 47907, USA
3 Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN 47907, USA


Figure 1
View larger version (39K):
[in this window]
[in a new window]

 
Fig. 1. Cell death after polyethylene glycol (PEG) application to acrolein-treated PC12 cells. (A–C) Control PC12 cells are shown developing on the culture substrate. Notice that these cells were well attached and some have extended processes giving them a stellate appearance. (A') The same culture as in A, 4 h after a `sham treatment' – the introduction of PBS into the culture medium. Notice that all cells in this field of view are healthy, developing and all together similar to the culture 4 h previously. (B') The same culture as in B, 4 h after the introduction of 100 µmol l–1 acrolein. Note the significant loss of cells with cell debris littering the substrate. (C') The same culture as in C, showing significant cell death as a result of acrolein treatment, in spite of the addition of 10 mmol l–1 PEG to the culture medium within 15 min after acrolein.

 

Figure 2
View larger version (9K):
[in this window]
[in a new window]

 
Fig. 2. Acrolein, mitochondrial functioning and polyethylene glycol (PEG). Absorbance (ordinate) is an index of mitochondrial function/oxidative metabolism. Note that control cells (untreated) showed characteristic MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) absorbance spectra and the addition of PEG to the medium did not affect the MTT assay. Mitochondrial function, however, is markedly compromised by the addition of 100 µmol l–1 acrolein, and this result is not affected by the inclusion of PEG in the assay medium. *Statistically significantly different from the control (P≤0.05).

 

Figure 3
View larger version (22K):
[in this window]
[in a new window]

 
Fig. 3. Polyethylene glycol (PEG) accumulates on the outside of PC12 cells. (A) 1 h after the addition of fluorescently decorated PEG, 3D confocal microscopy revealed that the only labeling above the limit of detection was confined to the surface of acrolein-treated cells. (B) By 2 h post treatment this same result was obtained, whereas at 3 h incubation time (data not shown), PEG was beginning to become apparent within the cells. These 2D representations, captured from 3D animated data sets, do not easily reveal the location of fluorescence when confined to the surface. Animating the 3D reconstruction, however, confirmed this surface labeling.

 

Figure 4
View larger version (30K):
[in this window]
[in a new window]

 
Fig. 4. The effects of polyethylene glycol (PEG) on CAP recovery following ischemia/acrolein reperfusion. (A) The double-sucrose gap-recording chamber. The device is constructed of PlexiglasTM with five separate chambers, all linked together by a narrow slot. Three large chambers are shown; the two end ones filled with KCl and the middle chamber with a physiological medium (a modified Krebs' solution), where a constant flow of medium through the chamber is carried out. The delivery to an `antechamber' reduces any turbulence or artifacts based on flow of medium through and out of the device. A delivery and an aspiration tube (that sets the fluid level) are shown for the central chamber and one of the small sucrose chambers to its right. A constant flow of sucrose significantly reduces the mixing of the KCl solution in the end chambers with the center one. A full length (~40 mm) of guinea pig spinal cord or a wedge-shaped long strip of only ventral white matter was placed across and within all five chambers. The ends of the dissected cord are then near intracellular potential, while the center of the cord is near extracellular potential. Bipolar stimulating electrodes fire compound action potentials (CAPs) at one end of the cord, and these are recorded arriving at the other end with bipolar recording electrodes. This arrangement provides a very precise recording of CAPs in cord for many hours at a time. It also allows the addition of test drugs or other interventions to be carried out in the central chamber. (B) The CAP amplitude profile in (a) the presence of oxygen and glucose deprivation (OGD), (b) OGD plus acrolein, and (c) OGD plus acrolein plus PEG. This graph displays the CAP amplitude recorded over a period of time. The values were normalized. Note the similarity in CAP amplitude recovery during the reperfusion period for groups (b) and (c). (C) The CAP waveforms are shown at three time points, (a) pre OGD, (b) at the end of OGD and (c) at the end of reperfusion, as indicated in B. Note there is little difference from the initial CAPs and the ones recorded following recovery from ischemia in OGD group. However, the amplitude is reduced to a half of pre-OGD levels in both groups (b) and (c). Scale bars, 1 mV, 1 ms.

 

Figure 5
View larger version (4K):
[in this window]
[in a new window]

 
Fig. 5. Compound action potential (CAP) recovery in oxygen and glucose deprivation (OGD), OGD plus acrolein, and OGD plus acrolein plus polyethylene glycol (PEG) groups. In the OGD alone group, there was a 97.6±7% recovery of the CAP following an ischemic insult (N=8). The CAP recoveries of the OGD plus acrolein and the OGD plus acrolein plus PEG groups were 46±5% and 45.7±4.6%, respectively. N=6 in each group. *P=0.88; Student's t-test, unpaired, two tail.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




© The Company of Biologists Ltd 2007